What a day for Hanmi Pharmaceutical Co. Ltd.'s investors. They must have thought they were in for a rally after the South Korean pharma firm made an announcement of a hefty licensing out deal with Genentech Inc. on Sept. 29. But their hopes soon turned to disappointment.
Hanmi's shares started the next day higher, but turned sharply lower after the company disclosed that Boehringer Ingelheim GMBH...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
